Last reviewed · How we verify
NCT07305727: EPICOL-R
A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer
trial in Uterine Cervical Neoplasms in 120 participants. Currently enrolling.
1 August 2026
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Nīmes |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 1 January 2026 |
| Primary completion | 1 August 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across France |
Conditions studied
- Uterine Cervical Neoplasms — all drugs for Uterine Cervical Neoplasms →
- Cervical Cancer by FIGO Stage 2018 — all drugs for Cervical Cancer by FIGO Stage 2018 →
Sponsor
Centre Hospitalier Universitaire de Nīmes
Who can join
18 and older, female only, with Uterine Cervical Neoplasms or Cervical Cancer by FIGO Stage 2018. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cervical cancer is the fourth most common cancer in women worldwide, with approximately 604,000 new cases in 2020.Treatment for locally advanced cervical cancer is based on a combination of radiotherapy and chemotherapy. The response to concomitant chemoradiotherapy vary from one woman to another. Predicting the response to these treatments would allow early consideration of alternative therapies for patients identified as less responsive to standard treatments. A 5-year recurrence-free survival is approximately 79% for stages IB and IIA and 59% for stages III and IVA, with approximately 36% of local failures despite chemoradiotherapy. In a few studies,the radiomic MRI approach in locally advanced cervical cancers has shown to be prognostic for locoregional recurrence or survival but these models still need to be explored and validated.The EPICOL cohort, a clinical-biological cohort of 136 patients treated with chemoradiotherapy for locally advanced cervical cancer at the Montpellier Cancer Institute or Nîmes University Hospital, will be used to develop a predictive model of response to chemoradiotherapy based on radiomic data from pelvic MRIs before and after treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07305727
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Uterine Cervical Neoplasms
Currently open trials in the same condition.
- NCT07011836 — Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women · NA · recruiting
- NCT06815939 — Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer · NA · recruiting
- NCT06558682 — Neoadjuvant Therapy in Cervical Cancer · NA · recruiting
- NCT06509724 — Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy · Phase 3 · recruiting
- NCT07202936 — Cervical Pre-cancer Treatment Failure Among Women Living With HIV in Zimbabwe · recruiting
Other Centre Hospitalier Universitaire de Nīmes trials
Trials by the same sponsor.
- NCT07403474 — Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Ther · Phase 4 · not yet recruiting
- NCT07455981 — Work Organization and Gambling Addiction · not yet recruiting
- NCT07403500 — Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain. · NA · not yet recruiting
- NCT07342010 — Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT · Phase 4 · not yet recruiting
- NCT07489963 — Functional Impact at 12 Months Post-op of Posterior Cruciate Ligament Conservation During Robotic-assisted Surgery (MAKO · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07305727 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nīmes
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07305727.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing